Cover Image
市場調查報告書

憂鬱症:流行病學、病患人數的市場預測,治療流程,已上市/開發平台藥物分析

Depression: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis

出版商 Datamonitor Healthcare 商品編碼 365214
出版日期 內容資訊 英文 275 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
憂鬱症:流行病學、病患人數的市場預測,治療流程,已上市/開發平台藥物分析 Depression: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis
出版日期: 2016年05月01日 內容資訊: 英文 275 Pages
簡介

憂鬱症治療藥的全球市場預計從2016年開始回歸正成長,不過,恢復多少取決於高風險臨床實驗的成敗。

在本報告提供憂鬱症的已上市/臨床實驗中 (開發平台上)的治療藥相關分析,各產品的市場規模的估計值,面臨「專利懸崖」狀態的市場規模的變化,及目前的有力品牌藥,應對未滿足需求的新產品的上市預測,治療指南和實際的處方行動的差異等相關調查。

市場預測:憂鬱症

  • 摘要整理
  • 市場概要與趨勢
  • 市場定義和分析方法
  • Abilify (Aripiprazole)
  • Brintellix (vortioxetine)
  • Cymbalta (Duloxetine)
  • esketamine
  • Fetzima (levomilnacipran)
  • Latuda (Lurasidone)
  • Lexapro (escitalopram)
  • Pristiq (desvenlafaxine)
  • Rexulti (brexpiprazole)
  • Seroquel (Quetiapine)
  • Viibryd (vilazodone)
  • Vraylar (cariprazine)
  • 一次調查技術

治療方法:憂鬱症

  • 摘要整理
  • 一次調查技術
  • 疾病定義與診斷方法
  • 患者的分類
  • 各國治療系統
  • 目前治療選擇
  • 處方的趨勢
  • 憂鬱症相關的未滿足需求

流行病學:美國、日本、歐洲的憂鬱症

  • 摘要整理
  • 疾病的背景情況
  • 資訊來源、分析方法
  • 市場預測:主要的憂鬱症性障礙
  • 市場預測:精神抑鬱症
  • 流行病學者的見解
  • 分析的優勢與限制

已上市藥物:憂鬱症

  • 摘要整理
  • 產品概要
  • 產品簡介:Abilify
  • 產品簡介:Brintellix
  • 產品簡介:Cymbalta
  • 產品簡介:Fetzima
  • 產品簡介:Lexapro
  • 產品簡介:Pristiq
  • 產品簡介:Rexulti
  • 產品簡介:Seroquel XR
  • 產品簡介:Viibryd

開發中產品:憂鬱症

  • 摘要整理
  • 臨床實驗開發平台概要
  • 產品簡介 (最後階段):ALKS 5461
  • 產品簡介 (最後階段):Vraylar
  • 產品簡介 (最後階段):esketamine

附錄

  • 附錄:憂鬱症的已上市藥物
  • 附錄:憂鬱症的開發中產品

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC4973

The depression market is likely to recover from a new low in 2016, although the extent of its resurgence will depend on the fate of high-risk clinical trials.

This report addresses the following questions:

  • How much value remains in the depression market, now that the patent cliff has passed?
  • As Lundbeck and Allergan go head-to-head in the SSRI and atypical antipsychotic classes, which of their new brands will become future market leaders?
  • What is the potential for Johnson & Johnson's esketamine as an antidepressant, considering its safety profile and regulatory barriers?
  • Which new and pipeline drugs address real unmet needs, contrasting with those that can be considered as me-too products?
  • How does real-world prescribing behaviour match treatment guidelines for major depression and dysthymia?

TABLE OF CONTENTS

FORECAST: DEPRESSION

  • 1. Executive Summary
  • 2. Market Overview and Trends
  • 3. Market Definition and Methodology
  • 4. Abilify (aripiprazole)
  • 5. Brintellix (vortioxetine)
  • 6. Cymbalta (duloxetine)
  • 7. esketamine
  • 8. Fetzima (levomilnacipran)
  • 9. Latuda (lurasidone)
  • 10. Lexapro (escitalopram)
  • 11. Pristiq (desvenlafaxine)
  • 12. Rexulti (brexpiprazole)
  • 13. Seroquel (quetiapine)
  • 14. Viibryd (vilazodone)
  • 15. Vraylar (cariprazine)
  • 16. Primary Research Methodology

TREATMENT: DEPRESSION

  • 17. Executive Summary
  • 18. Primary Research Methodology
  • 19. Disease Definition and Diagnosis
  • 20. Patient Segmentation
  • 21. Country Treatment Trees
  • 22. Current Treatment Options
  • 23. Prescribing Trends
  • 24. Unmet Needs in Depression

EPIDEMIOLOGY: DEPRESSION IN THE US, JAPAN, AND 5EU

  • 25. Executive Summary
  • 26. Disease Background
  • 27. Sources and Methodology
  • 28. Forecast: Major Depressive Disorder
  • 29. Forecast: Dysthymia
  • 30. Epidemiologist Insight
  • 31. Strengths and Limitations

MARKETED DRUGS: DEPRESSION

  • 32. Executive Summary
  • 33. Product Overview
  • 34. Product profile: Abilify
  • 35. Product profile: Brintellix
  • 36. Product profile: Cymbalta
  • 37. Product profile: Fetzima
  • 38. Product profile: Lexapro
  • 39. Product profile: Pristiq
  • 40. Product profile: Rexulti
  • 41. Product profile: Seroquel XR
  • 42. Product profile: Viibryd

PIPELINE: DEPRESSION

  • 43. Executive Summary
  • 44. Clinical Pipeline Overview
  • 45. Product profile (late stage): ALKS 5461
  • 46. Product profile (late stage): Vraylar
  • 47. Product profile (late stage): esketamine

APPENDIX

  • 48. Appendix: Marketed Drugs: Depression
  • 49. Appendix: Pipeline: Depression
Back to Top